Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Jiankang Yuan wins the "2019 Financial World Golden Wisdom Award for Outstanding Corporate Governance Practice Listed Company"

Published Time:

2019-08-06

On May 31, 2019, the "Financial World 2019 Value Discovery Carnival, the Second China Enterprise Value Development Forum, and the 'Jinzhi Award' China Enterprise Value Selection Award Ceremony," hosted by Financial World, was grandly held in Shenzhen. Themed "Connecting Science and Technology, Connecting Sustainable Growth," the event invited leaders from relevant departments, hundreds of outstanding listed companies, hundreds of institutional investors and industrial support funds, and authoritative media, bringing together upstream and downstream resources in industrial development to connect ideas and resources, and unleash value and strength.

As a major representative of China's large health industry, Joincare Pharmaceutical Group Industry Co., Ltd., with its outstanding performance in creating comprehensive economic, social, environmental, and governance value, won the "2019 Financial World Jinzhi Award for Outstanding Corporate Governance Practices Listed Company." Its market value and corporate governance have both received authoritative recognition.

 

 

It is understood that the Financial World website, which sponsors the award, was established in 1999. It is a leading domestic financial and economic information provider jointly invested by IDG (USA) and Vertex (Singapore), and is currently one of the most influential Chinese financial websites globally. The award selection criteria are rigorous and comprehensive, focusing on the exploration and effectiveness of domestic listed companies in the field of corporate governance in 2018. It uses factors such as equity structure, major shareholder shareholding changes, executive shareholding changes, and institutional shareholding changes as a base, and then, based on the disclosure of employee shareholding, equity incentive plans, and repurchase plans throughout 2018, constructs quantitative standards to screen listed companies with core competitiveness and significant contributions to industry development, selecting the best from the best and rewarding the outstanding ones. This time, HealthGen Pharma Group stood out among numerous listed companies, further demonstrating the company's outstanding corporate governance capabilities.

 

 

HealthGen Pharma Group's development and operating conditions in the medical and health care field have been affirmed by professional appraisal institutions and investors, leading to its receipt of the Jinzhi Award. In recent years, under the leadership of Mr. Zhu Baoguo, Chairman of the Board, HealthGen Pharma Group has developed into a professional and comprehensive pharmaceutical company with business covering raw materials, OTC, prescription drugs, and health products. It has also cultivated the domestic inhalation preparation market, with comprehensive product layouts. Its inhalation compound ipratropium bromide solution was approved for listing this year. In addition to its key layout of the inhalation preparation platform, the company is also striving to build a leading domestic and world-class biopharmaceutical and drug delivery technology platform for monoclonal antibodies and sustained-release microspheres, laying a solid foundation for the company's future development.